Codex
The Bottom Line from the Web
The most important web finding is that Religare is no longer a static post-fraud recovery story. It is now a promoter-transition and restructuring story: the Burman family completed control in February 2025, RBI removed Religare Finvest from its corrective action plan in July 2025, and management has since pushed a demerger that could leave REL effectively as a Care Health Insurance holding company by FY28.
That sounds constructive, but the web adds a second point the filings alone do not surface clearly enough: the governance cleanup is unfinished and the market is not paying up for the demerger yet. Care Health remains the main value driver, but it is also where the ESOP controversy and recent underwriting pressure are concentrated.
Promoter Stake (%)
Fresh Capital (₹ cr)
Care FY25 GWP (₹ cr)
Q3 FY26 Net Loss (₹ cr)
What Matters Most
Control has changed hands, but the transition is still in progress.
The Burman family completed its ₹2,116 crore open offer on February 20, 2025 and emerged with 25.16% of REL, then pushed its holding to about 30.3% by March 30, 2026 through market purchases, with Business Standard noting scope to exceed 34% after warrant conversion. That is a material change in who controls capital allocation and governance, even though the November 14, 2025 induction of Anand Burman, Mohit Burman, Aditya Burman, and Jimeet Modi was still described as subject to RBI approval. Sources: Livemint, Feb. 20 2025, Business Standard, Mar. 30 2026, Business Standard, Nov. 14 2025.
Religare Finvest’s RBI CAP exit is the cleanest positive surprise in the web corpus.
RBI said it had noted compliance with CAP conditions and changes in management and directors before withdrawing the restrictions on Religare Finvest with immediate effect. For investors, that matters more than the headline itself suggests: it improves the credibility of a lending restart, supports the case for carving RFL out as a separately listed vehicle, and marks a meaningful break from the old distressed narrative around the subsidiary. Source: Business Standard, Jul. 23 2025.
The demerger is the current thesis catalyst, but the market treated it as distant and messy.
REL approved the demerger on February 15, 2026: Care Health stays under REL, while lending, broking, and investment activities move to Religare Finvest, with RFL shares to be issued 1:1 and listing targeted for Q1 FY28. But the stock fell about 10% in the sessions after the announcement, and Mint argued that approvals may run through Q2 FY27 to Q4 FY27 before the scheme can realistically take effect, which turns the demerger into a multi-year execution story rather than a near-term rerating. Sources: Business Standard, Feb. 15 2026, Business Standard, Feb. 19 2026, Livemint, Feb. 23 2026.
Care Health is both the crown jewel and the current drag.
Moneycontrol reported that Care Health delivered FY25 gross written premium of ₹8,318 crore and held 5.6% market share, while Mint later described it as having more than 11% share, which likely reflects different market denominators rather than a factual impossibility. What is clearer is that profitability worsened: Mint said Care posted a ₹111 crore loss in Q3 FY26 and that its combined ratio widened to 109.6% in 9MFY26 from 105.2% a year earlier, even as the demerger would leave REL heavily dependent on this business. Sources: Moneycontrol, Feb. 3 2026, Livemint, Feb. 23 2026.
The Rashmi Saluja overhang did not disappear with her exit.
IRDAI fined Care Health ₹1 crore in July 2024 and ordered it to buy back 7.57 million vested ESOP-linked shares from Rashmi Saluja at ₹45.32 apiece while cancelling the remaining grants; SAT later stayed the order but barred her from dealing in the shares. The matter stayed alive in 2025 and 2026: InGovern publicly asked for an update on a ₹480 crore clawback in July 2025, and on January 28, 2026 the Bombay High Court refused to quash the FIR and ECIR against Saluja, citing “abundance of incriminating material” in the PMLA-linked case. Sources: Moneylife, Jul. 24 2024, Business Standard, Aug. 9 2024, Livemint, Jul. 13 2025, Free Press Journal, Jan. 28 2026.
The turnaround required fresh money sooner than the equity story implied.
In March 2025, REL said it had commissioned a governance review of itself and subsidiaries and that the board had identified a cash-flow gap over the next few months, prompting it to seek immediate promoter support. Four months later, the company announced a ₹1,500 crore capital commitment led by the Burman family, including ₹750 crore from the promoter group at ₹235 per warrant, which is both a signal of sponsor backing and evidence that the cleanup needed capital, not just new rhetoric. Sources: Business Standard, Mar. 17 2025, Business Standard, Jul. 11 2025.
Recent News Timeline
The three-month news flow is unusually concentrated around one issue: the market is trying to decide whether the Burman-led demerger creates a cleaner holding-company story or merely repackages unresolved governance and insurance underwriting problems. There was no comparable flow of credible positive analyst upgrades or new institutional sponsorship in the available corpus.
What the Specialists Asked
Insider Spotlight
Rashmi Saluja: The web record is dominated by the Care Health ESOP controversy and insider-trading allegations rather than by operating performance. The main investor takeaway is not just that she lost control, but that the legal tail from her tenure is still attached to the asset REL is most likely to be valued on. Sources: Moneycontrol, Free Press Journal.
Burman family: Mohit, Anand, and Aditya Burman have moved from hostile acquirers to the effective control group, and the subsequent ₹750 crore promoter contribution to the ₹1,500 crore raise suggests they are willing to fund the transition. The important unresolved point is formal governance completion, because board induction was still described as subject to RBI approval when announced in November 2025. Sources: Business Standard, Business Standard.
Jimeet Modi: His addition alongside the Burman nominees suggests the new promoter wants market-facing financial-services expertise around the board table, not only family representation. The web corpus did not surface compensation disclosures or a materially separate insider-trading pattern for him. Source: The Hindu BusinessLine. Confidence: limited evidence.
Industry Context
The broader backdrop is supportive for Care Health in one sense and tougher in another. Moneycontrol reported that India’s standalone health insurance market grew from roughly ₹63,700 crore in FY21 to ₹1,18,688 crore in FY25, while Star Health’s dominance fell sharply, creating room for challengers. Source: Moneycontrol, Nov. 11 2025.
But the web also shows why investors are not automatically rewarding REL for owning Care Health. Mint’s February 2026 analysis points to rising healthcare costs, higher claims, and a worsening combined ratio at Care, which means the sector tailwind is being partly offset by underwriting stress and operating inefficiency. Source: Livemint, Feb. 23 2026.